Arkadios Wealth Advisors Trims Holdings in Stryker Co. (NYSE:SYK)

Arkadios Wealth Advisors trimmed its position in Stryker Co. (NYSE:SYK) by 30.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 729 shares of the medical technology company’s stock after selling 317 shares during the period. Arkadios Wealth Advisors’ holdings in Stryker were worth $218,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Quarry LP purchased a new position in Stryker in the 1st quarter valued at about $27,000. Freedom Wealth Alliance LLC purchased a new position in shares of Stryker during the 4th quarter worth about $26,000. Rise Advisors LLC lifted its holdings in shares of Stryker by 692.9% during the 3rd quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 97 shares during the period. Finally, Cornerstone Planning Group LLC purchased a new position in shares of Stryker during the 2nd quarter worth about $38,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock valued at $72,845,768 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on SYK. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a report on Wednesday, January 31st. Wells Fargo & Company increased their price objective on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $360.00 price objective on shares of Stryker in a report on Thursday, February 15th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and increased their price objective for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Stryker Stock Up 0.3 %

Shares of NYSE:SYK opened at $350.86 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a 50 day moving average of $350.48 and a two-hundred day moving average of $309.48. The company has a market capitalization of $133.49 billion, a price-to-earnings ratio of 42.53, a price-to-earnings-growth ratio of 2.82 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the company earned $3.00 earnings per share. Stryker’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.